As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval

In 2017, the WHO designated clarithromycin-resistant H. pylori, a bacterial infection that affects more than half of the global population, a high priority for antibiotic research and development. On Monday, Israel’s RedHill Biopharma secured FDA approval for its rifabutin-based regimen to address the alarming rates of resistance to standard-of-care therapies.